Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
about
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cellsThe relationship between nutrition and prostate cancer: is more always better?Combined treatment with troglitazone and lovastatin inhibited epidermal growth factor-induced migration through the downregulation of cysteine-rich protein 61 in human anaplastic thyroid cancer cellsLovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevanceHigh-dose lovastatin for acute ischemic stroke: results of the phase I dose escalation neuroprotection with statin therapy for acute recovery trial (NeuSTART)Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitorsInhibiting HDAC1 Enhances the Anti-Cancer Effects of Statins through Downregulation of GGTase-Iβ ExpressionExploiting the critical perioperative period to improve long-term cancer outcomesDietary geranylgeraniol can limit the activity of pitavastatin as a potential treatment for drug-resistant ovarian cancerOxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cellsThe Neuroprotection with Statin Therapy for Acute Recovery Trial (NeuSTART): an adaptive design phase I dose-escalation study of high-dose lovastatin in acute ischemic stroke.Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumorsmTORC2 is required for proliferation and survival of TSC2-null cells.SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.Simvastatin Enhances the Effects of Radiotherapy and Cetuximab on a Cell Line (FaDu) Derived from a Squamous Cell Carcinoma of Head and NeckSynergic effect of eicosapentaenoic acid and lovastatin on gene expression of HMGCoA reductase and LDL receptor in cultured HepG2 cellsSimultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosisDifferential effects of lovastatin on cisplatin responses in normal human mesothelial cells versus cancer cells: implication for therapy.Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapyLovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.Transgelin 2 participates in lovastatin-induced anti-angiogenic effects in endothelial cells through a phosphorylated myosin light chain-related mechanism.Cholesterol biosynthesis and homeostasis in regulation of the cell cycle.Molecular mechanisms underlying the effects of statins in the central nervous system.Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cellsMicroarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomasEffects of statins on the risk of hepatocellular carcinomaLipid-lowering properties of TAK-475, a squalene synthase inhibitor, in vivo and in vitro.Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.Synergistic anticancer effects of combined γ-tocotrienol with statin or receptor tyrosine kinase inhibitor treatment.Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.Novel effects of simvastatin on uterine fibroid tumors: in vitro and patient-derived xenograft mouse model study.Lovastatin protects human endothelial cells from the genotoxic and cytotoxic effects of the anticancer drugs doxorubicin and etoposideHMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphomaInhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase (PI3K)/AKT pathways.Anticancer activity of the cholesterol exporter ABCA1 gene.Fluvastatin inhibits FLT3 glycosylation in human and murine cells and prolongs survival of mice with FLT3/ITD leukemia.A statin-regulated microRNA represses human c-Myc expression and function.Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese RatsStatins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hoursA phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies
P2860
Q21093314-A28A3F07-0964-40CF-A9CC-4AD0EFC89391Q24604956-1B1DF85E-21FA-4BBD-94AC-E6D30801E4E6Q28543879-046A0E0B-2FAD-48E6-81BF-C42B893B67CEQ33542856-091A5273-8CA6-4997-8DC2-0E7CECA1DF69Q33621245-111E16CA-B570-4140-9A7C-949D281AB693Q33691348-81C554A0-086C-4C7B-9524-D6CB7A33EF01Q33755131-57E812E5-C16C-4C19-AC2B-35E685FA7199Q33871661-046D8E15-E172-478F-9D83-7C811682F91EQ33906118-408AB8FC-BC09-46E8-8056-A8D1E8FDBA82Q33917134-7E3C738D-2A91-402D-AC19-134F5BCC7045Q34034752-F620AADD-B929-4097-874D-61587B33254DQ34141720-48C9520A-9468-42E7-9B19-EE1588E4CCBCQ34177457-A8AD07AB-D771-475A-8C3C-E55080325705Q34302258-50C00AC3-7D4B-4DE8-A525-E8F729E76341Q34369305-3CF3D369-0ED5-40E3-AC90-C3BFDCD86DE4Q34404997-E3F07952-0763-4D57-8C33-14AC1F529922Q34413892-D17E0AB0-52E8-4795-8DB9-756E07834C91Q34428844-51DC6C12-E55D-48EF-8A21-FB3510905F67Q34429244-BEDB6F50-6A5A-4B4D-8005-071AEFF13464Q34430735-C4708A1E-2433-4949-A167-B91C0DE6C17AQ34441557-53A8B251-7B62-45D0-8713-BFF77E6A4176Q34648398-287E14BE-A901-4507-803E-E469C4EE4696Q34685463-A812240C-C6E7-4749-ABAF-77B699C3C778Q34696107-8A03AE51-95CA-4B82-B6C5-C077B0FEACC2Q34929092-4A67FFB7-0B8B-4C11-AA52-066651C0B387Q34997752-88B60528-83C3-4002-AC80-5F4CCB0C97F7Q35045471-F82C93E5-4DD0-4CF9-AA6D-A23BF16507CDQ35200765-3F5687A5-3E86-4076-9E0E-56F3393C342FQ35648936-08C112F9-AA20-4135-8A25-61193DD7FC07Q35750986-B9ADA595-DA71-4306-9464-5DC29B08B0E0Q35901096-5A96E5B4-9A4D-4CD7-B97F-1A070292BFF8Q36054324-E27ED955-6A18-488E-9A95-2B39A119E564Q36108705-589C4453-3C1C-439D-AC75-6DAE6535555FQ36124790-EA367832-64C5-4D9D-AD7E-B5AD921DDF48Q36291341-39C78A72-CDB7-481F-BDD0-1DDC8DD70C5CQ36318153-9BE9049A-0568-4386-BF08-C7668CE2229AQ36379501-04237F08-7359-4476-98C2-7F4163C51A75Q36640423-97DBEC05-BC66-4068-9AB6-4BF1F9ABEED7Q36725215-F26F4585-CE80-4FE0-88E5-25664EEB39E4Q36748775-230260D8-8F67-45B7-886F-5191EF6B9435
P2860
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
description
1996 nî lūn-bûn
@nan
1996 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի մարտին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@ast
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@en
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@nl
type
label
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@ast
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@en
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@nl
prefLabel
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@ast
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@en
Phase I study of lovastatin, a ...... hway, in patients with cancer.
@nl
P2093
P1476
Phase I study of lovastatin, a ...... thway, in patients with cancer
@en
P2093
Patronas N
Thibault A
Tompkins AC
P304
P407
P577
1996-03-01T00:00:00Z